indinavir-sulfate and Atrophy

Topics: Atrophy; Child, Preschool; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Kidney Calculi; Kidney Cortex

Topics: Adult; Atrophy; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypertension; Indinavir; Kidney

A human immunodeficiency virus type 1 (HIV)-seropositive, antiretroviral-naive patient presented with significant cognitive dysfunction. Neuropsychologic, neuroradiologic, immunologic, and virologic studies confirmed HIV-associated dementia (HAD). After 12 weeks of highly active antiretroviral therapy (HAART) with ibuprofen, dramatic improvements were demonstrated in neurologic function and were sustained for > 1 year. HIV-1 RNA in cerebrospinal fluid (CSF) decreased from 10(5) to 10(4) copies/mL after 4 weeks. After 20 weeks of therapy, plasma viremia decreased from 10(6) copies/mL to undetectable (< 96 copies/mL). Assays of neurotoxins (tumor necrosis factor-alpha, quinolinic acid, and nitric oxide) in plasma and CSF were considerably elevated at presentation and significantly decreased after therapy. Baseline plasma and CSF demonstrated neurotoxic activities in vitro, which also reduced markedly. These data, taken together, support the notion that HAD is a reversible metabolic encephalopathy fueled by viral replication. HAART used with nonsteroidal antiinflammatory agents leads to the suppression of inflammatory neurotoxins and can markedly improve neurologic function in HAD.

Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Atrophy; Brain; Female; Humans; Ibuprofen; Indinavir; Lamivudine; Magnetic Resonance Imaging; Neurons; Neurotoxins; Nitric Oxide; Quinolinic Acid; Toxicity Tests; Tumor Necrosis Factor-alpha; Zidovudine